Humacyte, Inc. (HUMA)
(Delayed Data from NSDQ)
$3.99 USD
+0.09 (2.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.98 -0.01 (-0.25%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
HUMA 3.99 +0.09(2.31%)
Will HUMA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HUMA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HUMA
Should You Buy Humacyte (HUMA) Ahead of Earnings?
Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma
HUMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q2 Loss, Tops Revenue Estimates
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates
Other News for HUMA
OPI, RVNC and AQST are among after hour movers
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday
Commit To Buy Humacyte At $2.50, Earn 42.4% Annualized Using Options
Tommy Tuberville Trades Raise Eyebrows Again: Senator Sells Put Options, Buys Small Biotech Linked To Ukraine-Russia War